Kohl Pam
Independent Researcher, Raleigh, NC, United States.
Front Nucl Med. 2023 Feb 27;3:1127692. doi: 10.3389/fnume.2023.1127692. eCollection 2023.
Most radiopharmaceuticals are intravenously administered during nuclear medicine imaging or therapy procedures. When a nuclear medicine clinician delivers some or all of a radioactive drug into a patient's healthy tissue rather than the vein as intended, a patient experiences an extravasation. Radiopharmaceutical extravasations provide zero patient benefit and considerable potential downsides, depending on the severity of the extravasations. What nuclear medicine patients want and need regarding the administration of radiopharmaceuticals is transparency. And yet in the year 2023, little transparency exists regarding these extravasations. From the patient perspective, transparency regarding extravasations is essential to improving care, ensuring radiation protection, reducing health inequities, and untangling the deeply disturbing and irregular relationship between the nuclear medicine community and their regulating body, The U.S. Nuclear Regulatory Commission. Transparency is also critical to help address many other questions regarding radiopharmaceutical extravasations.
大多数放射性药物是在核医学成像或治疗过程中通过静脉注射给药的。当核医学临床医生将部分或全部放射性药物注入患者的健康组织而非预期的静脉时，患者就会发生外渗。放射性药物外渗对患者没有任何益处，而且根据外渗的严重程度，还存在相当大的潜在不利影响。核医学患者在放射性药物给药方面想要和需要的是透明度。然而，在2023年，关于这些外渗情况几乎没有透明度可言。从患者的角度来看，外渗情况的透明度对于改善护理、确保辐射防护、减少健康不平等以及理清核医学领域与其监管机构美国核管理委员会之间令人深感不安且不正常的关系至关重要。透明度对于帮助解决许多其他有关放射性药物外渗的问题也至关重要。
